Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial

Jonathan Fuchs,1,2 Connie Celum,2,3,4 Jing Wang,5 James Hughes,6 Jorge Sanchez,7,8 Frances Cowan,9 Stewart Reid,10 Sinead Delany-Morettwe,9 Lawrence Corey,11,12 and Anna Wald,4,5,7,8

1HIV Research Section, San Francisco Department of Public Health, and 2Department of Medicine, University of California, San Francisco; Departments of 3Global Health, 4Medicine, 5Epidemiology, 6Biostatistics, and 7Laboratory Medicine, University of Washington, and 8Vaccine and Infectious Diseases Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington; 9Department of Medicine, University of Alabama, Birmingham; 10Asociación Civil Salud y Educación, Impacta, Lima, Peru; 11Royal Free and University College Medical School, University College London, London, United Kingdom; 12Centre for Infectious Disease Research, Lusaka, Zambia; 13Reproductive Health and HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa

Acyclovir suppressive therapy (400 mg twice daily) reduces herpes simplex virus (HSV) type 2–associated genital ulcer disease and lesional HSV shedding. In an international trial of acyclovir for suppression of HSV type 2 to prevent human immunodeficiency virus (HIV) acquisition (HIV Prevention Trials Network 039), acyclovir had a smaller effect on the frequency of genital ulcer disease as well as a smaller effect on the frequency and quantity of lesional HSV DNA in African women and Peruvian men, compared with its effects in men in the United States. The observed regional variation in the clinical and virologic efficacy of acyclovir for HSV suppression warrants further evaluation of determinants of responses to acyclovir. (ClinicalTrials.gov identifier: NCT00076232.)

Herpes simplex virus type 2 (HSV-2) is the most common etiology of genital ulcer disease (GUD) worldwide and has been associated with a 2–4-fold increase in acquisition of human immunodeficiency virus (HIV) [1]. It is hypothesized that increased HIV acquisition risk is conferred by breaches in genital epithelium, as well as genital inflammation during reactivation of herpes simplex virus (HSV). Herpetic ulcerations compromise the integrity of genital epithelium and mucosa and recruit activated CD4+ and CD8+ T lymphocytes and dendritic cells that may facilitate HIV attachment and infection during sexual intercourse [2].

We recently completed a randomized placebo-controlled trial (HIV Prevention Trials Network [HPTN] 039) to evaluate whether 400 mg of acyclovir twice daily could reduce HIV acquisition among 3172 HSV-2–seropositive men who have sex with men (MSM) in the United States and Peru and women in sub-Saharan Africa by suppressing HSV [3]. This trial failed to demonstrate a protective effect of this regimen on the incidence of HIV acquisition, confirming the results of another trial that tested the same intervention in Tanzanian women [4]. As a secondary objective, HPTN 039 evaluated the impact of acyclovir on symptomatic genital ulcers, as well as on virologic end points, defined by the frequency and amount of HSV detected in genital ulcers that are observed on examination. The efficacy of acyclovir has been extensively characterized in developed countries; however, there is a paucity of data on acyclovir efficacy in resource-poor countries. Although acyclovir has now been added to the World Health Organization list of essential drugs, many sexually transmitted disease treatment clinics in Africa still do not have access to the drug, and the cost of the medication limits its use. In addition, evaluation of acyclovir in resource-poor settings has focused on treatment of GUD and not on prevention of HSV reactivation. Thus, our trial provides novel information about the clinical and virologic efficacy of suppressive acyclovir in resource-poor settings.

Methods. A total of 3127 evaluable HIV-negative, HSV-2–antibody–positive participants were enrolled into the HPTN 039 trial. MSM were enrolled at sites in the United States (Se-
attle, WA; San Francisco, CA; and New York, NY) and Peru
(Lima, Iquitos, and Pucallpa), and women were enrolled at
sites in Harare, Zimbabwe; Lusaka, Zambia; and Johannesburg,
South Africa. Informed consent was obtained from study par-
ticipants, and institutional review boards approved the protocol
at each participating trial site. Eligibility criteria and screening
procedures are described in further detail elsewhere [3].

Participants were randomized to receive 400 mg of acyclovir
or a matching placebo twice daily and were seen monthly for
12–18 months. During monthly visits, participants were asked
about symptoms of genital herpes in the past 7 days. Clinicians
performed a genital examination at all quarterly study visits
and at any monthly or interim study visit if symptoms of genital
ulcers were reported. The study staff obtained swab specimens
from lesions clinically consistent with a herpes recurrence; swab
specimens were placed into polymerase chain reaction (PCR)
medium, frozen, and shipped to the virology laboratory at the
University of Washington. An HSV DNA PCR assay was per-
formed according to validated, previously published proce-
dures [5, 6]. Samples were analyzed using a real-time fluores-
cent probe–based PCR assay (TaqMan; Applied Biosystems) to
quantitate HSV, and results were considered positive for HSV-
2 if >3 copies/reaction, or 150 copies/mL of fluid, were detected
[7]. Means, medians, and standard deviations of HSV-2 DNA
copy counts from genital ulcer specimens were calculated by
study arm, and the distribution for log_{10} HSV PCR titer was
plotted by study arm and region. Monthly and quarterly rates
of adherence to the study drug regimen were computed on the
basis of monthly pill counts from returned study drug bottles
and self-reports. Because each participant provided swab sam-
ples at up to 6 different study visits, we used generalized esti-
mated equations to analyze numbers of cases of GUD, HSV-
2 positivity from lesional swab specimens, and mean log_{10} HSV
copy counts. Models for mean reduction in HSV were adjust-
ed for age and report of genital ulcers in the 3 months prior
to enrollment. To explore whether reductions in HSV shedding
were affected by adherence to the study drug, analyses were
stratified by adherence level as measured by monthly pill
counts averaged for the preceding quarter (≤90% and >90%).
For counts (ie, numbers of cases of GUD) and binary results
(HSV-2 positivity), a log link and negative binomial distribution
was used. For continuous outcomes (ie, log_{10} HSV DNA copy
counts), an identity link and normal distribution was used. An
independence working correlation and a robust covariance es-
timate were used in all analyses.

Results. A total of 459 MSM were enrolled at US sites, a
total of 1355 MSM were enrolled at Peruvian sites, and a total
of 1358 women were enrolled at African sites. At baseline, 131
(29%) of the US MSM and 227 (17%) of the Peruvian MSM
reported having had anogenital herpes symptoms over the prior
3 months; 3% of men from each region received a clinical
diagnosis of GUD at enrollment. In contrast, 443 (33%) of the
women reported symptoms over this time period and 225
(17%) received a diagnosis of GUD on examination. During
the 18-month study follow-up period, 915 (29%) of the 3172
total participants received a diagnosis of GUD on examination,
for a total of 1664 episodes detected. The GUD incidence varied
by study arm and population. The overall rate of GUD diag-
nosis on examination was 55 cases per 100 person-years in the
placebo group compared with 30 cases per 100 person-years
in the acyclovir group (P < .001). For the US MSM, the rate of
GUD was 53 cases per 100 person-years in the placebo group,
compared with 15 cases per 100 person-years in the acyclovir
group. For the Peruvian MSM, the rate of GUD was 34 cases
per 100 person-years in the placebo group compared with 16
cases per 100 person-years in the acyclovir group. For the Af-
rican women, the rate of GUD was 75 cases per 100 person-
years in the placebo group, compared with 46 cases per 100
person-years in the acyclovir group. Overall, acyclovir was as-
associated with a 47% reduction in the incidence of GUD (relative
risk [RR], 0.53 [95% confidence interval {CI}, 0.46–0.62]); the
associated reduction was 71% in US MSM (RR, 0.29 [95% CI,
0.18–0.47]), but it was only 53% in Peruvian MSM (RR, 0.47
[95% CI, 0.36–0.62]) and 39% in African women (RR, 0.61
[95% CI, 0.51–0.74]; P < .001 for the difference in treatment
effect by region). Thus, we observed statistically significant re-
gional variation in the proportional reduction in the incidence
of GUD with acyclovir suppression.

To explore these differences, we examined virologic data ob-
tained from 1468 swab specimens collected from participants
with GUD. Overall, 861 (59%) of the 1468 swab specimens
tested positive for HSV-2 (630 of 962 in the placebo arm com-
pared with 311 of 506 in the acyclovir arm; P < .001). This
represented a 63% reduction in the incidence of ulcers with
detectable HSV-2, although regional differences persisted. We
found an 88% reduction in the incidence of HSV-2–positive
breakthrough genital ulcers among enrolled US MSM (97 of
137 in the placebo arm compared with 12 of 43 in the acyclovir
arm; RR, 0.12 [95% CI, 0.05–0.29]), but only a 61% reduction
in Peruvian MSM (185 of 261 in the placebo arm compared
with 71 of 121 in the acyclovir arm; RR, 0.39 [95% CI, 0.28–
0.56]), and a 57% reduction in African women (348 of 564 in
the placebo arm compared with 148 of 342 in the acyclovir
arm; RR, 0.43 [95% CI, 0.34–0.56]; P < .001 for the difference
in RR between regions). Of the samples with detectable HSV,
the mean HSV-2 DNA copy number detected in lesions was
reduced by 0.43 log_{10}. However, as shown in Figure 1, the re-
duction was highest among US MSM: there was an observed
1.07 log_{10} reduction with acyclovir (95% CI, 0.33–1.80 log_{10}
copies; P = .004) among US MSM, a 0.68 log reduction (95% CI,
0.04–1.32 log_{10} copies; P = .04) among Peruvian MSM, and
only a 0.32 log_{10} reduction (95% CI, 0.01–0.63 log_{10} copies;
Figure 1. Comparison of herpes simplex virus (HSV) DNA copy counts in 861 swab specimens with detectable HSV from genital ulcers, by study arm and by region. The number of swab specimens (N) and the mean, median, and standard deviation (SD) of the HSV DNA log10 copy count is provided for participants randomized to receive placebo (left) or acyclovir (right).

P = .05) among the African women (P = .13 for the difference between regions). As shown in Table 1, these estimates were minimally affected when adjusted for age and reported history of GUD in the 3 months prior to enrollment. In an unadjusted model restricting the analysis to swab specimens with detected HSV-2 collected from participants reporting >90% adherence to the treatment regimen, as measured by average adherence in the preceding quarter (n = 627 swab specimens), the mean reduction in the log10 HSV DNA copy count increased marginally in all groups, but regional differences persisted (1.31 log10 HSV DNA copy reduction in the US MSM, 0.89 in the Peruvian MSM, and 0.47 in the African women; P = .30 for the difference between regions).

Discussion. In this large, multisite, international trial of suppressive HSV-2 therapy, the standard dose of twice daily acyclovir reduced the incidence of GUD recurrence by half overall, reduced the incidence of ulcers with detectable HSV-2 by 63%, and reduced the HSV DNA copy count in samples

Table 1. Reductions in Herpes Simplex Virus (HSV) DNA Copy Count in Patients Who Received Acyclovir, Compared with Patients Who Received Placebo, by Region

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of swab specimens</th>
<th>Mean reduction in log10 copy count (95% CI)</th>
<th>P for overall valuea</th>
<th>US MSM</th>
<th>Peruvian MSM</th>
<th>African women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted</td>
<td>861</td>
<td>0.43 (0.15–0.71)</td>
<td>.003</td>
<td>1.07 (0.33–1.80)</td>
<td>0.68 (0.04–1.32)</td>
<td>0.32 (0.01–0.63)</td>
</tr>
<tr>
<td>Adjustedb</td>
<td>861</td>
<td>0.46 (0.18–0.75)</td>
<td>.001</td>
<td>1.12 (0.40–1.84)</td>
<td>0.70 (0.05–1.34)</td>
<td>0.32 (0.01–0.64)</td>
</tr>
<tr>
<td>&gt;90% Adherencec</td>
<td>627</td>
<td>0.57 (0.25–0.89)</td>
<td>.001</td>
<td>1.31 (0.20–2.42)</td>
<td>0.89 (0.15–1.63)</td>
<td>0.47 (0.11–0.83)</td>
</tr>
</tbody>
</table>

NOTE. Patients were HSV-positive patients with genital ulcer disease (GUD). CI, confidence interval; MSM, men who have sex with men.

a P-value for overall reduction associated with acyclovir compared with that associated with placebo.
b Generalized estimated equation multivariate analysis adjusted for age and baseline report of GUD symptoms in the 3 months prior to enrollment.
c Unadjusted analysis restricted to swab specimens collected from MSM and women with >90% average quarterly adherence to the study drug regimen, as measured by monthly pill count.
from those ulcers by 0.43 log_{10} copies. However, we observed significant regional variation in the incidence of GUD diagnosis on examination, as well as the frequency and amount of HSV detected in specimens from ulcers in US and Peruvian MSM and African women. These differences by region in the quantity of HSV-2 detected in swab specimens from genital herpes lesions persisted after adjusting for level of adherence to antiviral therapy in the preceding quarter, and thus they are unlikely to be explained by inadequate drug intake. Other possible explanations for the lower efficacy of acyclovir on GUD-associated HSV-2 shedding in populations outside the United States, particularly in Africa, include strain variation, resulting in inherent acyclovir resistance among HSV strains from Africa, or unappreciated differences in acyclovir absorption or pharmacokinetics. Detailed studies with frequent assessment of genital shedding combined with drug level evaluation may elucidate the mechanism underlying our observations.

The substantial body of evidence establishing the efficacy of acyclovir suppression on clinical and subclinical HSV shedding comes from studies of US and European cohorts [8, 9]. For example, a recent study by Gupta and colleagues [10] that enrolled men and women at research clinics in the Northwest United States observed a 1.2–1.6 log_{10} reduction in HSV DNA copy number by means of PCR in a comparison of acyclovir and valacyclovir with placebo; this result mirrors our estimates for US participants. Despite increased use of acyclovir worldwide for syndromic management of HSV-2, data are limited on the efficacy of suppressive HSV therapy in resource-poor settings. However, over the past several years, studies in Peru [11] and Africa [12] evaluating HSV-2 suppression with both drugs to reduce HIV shedding and disease progression among HIV-infected men and women have also shown efficacy in reducing HSV-2 viral shedding, on the basis of molecular diagnostic methods similar to those used in the present study. The authors of the Tanzanian trial [4] suggested that suboptimal adherence to a regimen of 400 mg of acyclovir twice daily may account for the lack of efficacy in reducing the incidence of HIV acquisition among the HIV-negative women enrolled in their study, as evidenced by a lower than anticipated reduction in HSV shedding from cervicovaginal lavage specimens. However, in our study, adherence rates, measured primarily by pill count, were >90% on average [3]. Moreover, our GUD analysis showed only marginal improvements in the reduction of HSV shedding across all groups when the analysis was restricted to those with the highest level of adherence.

A limitation of this analysis is that we did not perform HSV cultures at the time of GUD swab sampling, which would have permitted us to phenotype viral isolates for acyclovir sensitivity, nor did we perform genotypic assays to determine whether populations outside the United States had a greater prevalence of acyclovir resistance, although future studies are planned. Given that acyclovir resistance is infrequent among immunocompetent persons from settings with high levels of background acyclovir use [13], it is unlikely that resistance from this mechanism would be observed in Peru and Africa, where acyclovir availability remains very limited.

Regional differences in HSV-2 shedding, despite suppressive therapy, were unexpected and may have several implications. Potential biological explanations require further exploration to assess differential effects of acyclovir by population. Thus far, liquid chromatography performed on study drug stored in the field has confirmed expected drug potency [3], and studies are currently underway to assess pharmacokinetics and GUD healing among African women treated with standard episodic acyclovir dosing. In addition, HSV-2 genotypic strain variation has been reported [14], and although an association with lower susceptibility to acyclovir has not been observed, further study of viral polymorphisms as a potential explanation for the regional differences in acyclovir response is warranted. Of note, although our study relied on pill count and self-report to measure adherence to the study regimen, as is the standard for most biomedical prevention trials, these methods may overestimate adherence [15]. Finally, efforts to identify a safe and effective HSV-2 vaccine must continue, to reduce the burden of new HSV-2 infections globally and potentially reduce HIV transmission risk in those regions most affected by the epidemic.

Acknowledgments

We thank Scott Rose and Sam Griffith of Family Health International, for study implementation support. We acknowledge Dr Susan Buchbinder and Theresa Wagner, for their input on the manuscript, and the extraordinary commitment of the HIV Prevention Trials Network 039 trial sites, volunteers, and participating community advisory boards.

References

1168 • JID 2010:201 (15 April) • BRIEF REPORT


